Stocks
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -11.6 | -8.21 | -7.58 | -1.25 | -0.50 | -1.54 | ||
| Changes by years, y/y, % | +2 508% | -29% | -8% | -84% | -60% | +2.4% | |||
Allogene Therapeutics. EV/EBITDA
Allogene Therapeutics. EV/EBITDA, changes, %
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EV/EBITDA | ? | -0.47 | -0.61 | -1.73 | -0.36 | -1.41 | -1.54 | |
| Changes by years, y/y, % | -87% | -53% | +100% | -62% | +200% | |||
| Changes by quarters, q/q, % | -50% | +31% | +181% | -79% | +292% | |||
